Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit.

The authors assessed the ocular toxicity and pharmacokinetics of subconjunctivally and intravenously administered cyclosporine in New Zealand white rabbits. Fifteen rabbits received a subconjunctival injection of 5 (five animals), 10 (five animals) or 25 (five animals) mg of cyclosporine in 0.1 mL (intravenous solution of Sandimmune [50 mg/mL]); 5 mg was found to be the maximum tolerable dose.

Effect of subconjunctivally administered antineoplastics on experimentally induced intraocular malignant tumour.

Twice-weekly subconjunctival injections of 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), cytarabine (ARA-C) and methotrexate (12.5 mg, 20 mg, 75 mg and 12.5 mg per dose respectively) were used to treat Greene melanoma implanted in the anterior chamber of the eyes of three groups of New Zealand rabbits: group 1 (14 animals), the control group, received saline, group 2 (16 animals) received treatment beginning immediately after tumour implantation and group 3 (15 animals) received treatment starting 1 week after implantation.

Cyclic alternating chemotherapy for small cell carcinoma of the lung.

Eighty-two previously untreated patients with small cell cancer of the lung were treated with six cycles of two alternating drug regimens: a new combination of mitomycin, methotrexate, and etoposide; and cyclophosphamide, doxorubicin, and vincristine. No maintenance chemotherapy was used. Consolidative thoracic irradiation and prophylactic cranial irradiation were employed.

Ocular absorption and toxicity of methotrexate in the dog.

The ocular absorption, elimination and toxicity of 12.5 mg of methotrexate in 0.5 cc administered subconjunctivally was studied in the dog.

5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules.

Ninety-four patients with advanced colorectal adenocarcinoma were treated by continuous iv 5-FU infusion on three different dose schedules. Thirty-three patients received a 72-hour infusion of 5-FU (30 mg/kg/24 hours) every 3 weeks (Group A); 31 received a 72-hour infusion of 5-FU (30 mg/kg/24 hours) every 2 weeks (Group B); and 30 received a 48-hour infusion of 5-FU (30 mg/kg/24 hours) every week (Group C). Although this was a sequential nonrandomized study of the dose schedules, the groups were comparable with respect to various prognostic factors.